PTO/SB/96 (11-08)

Approved for use through 12/31/2085. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)

Visinan Biotechnologies Inc.

Application owner.	
Application No./Patent No.: 10/007,621 / 7,211,414	Filed/Issue Date: December 03, 2001 / May 01, 2007
Entitled: ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS MONOMER INCORPORATION FIDELITY	AND METHODS FOR ALTERING
	poration
(Name of Assignee) (Ty	pe of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:	
 the assignee of the entire right, title, and interest; or 	
an assignee of less than the entire right, title and interc (The extent (by percentage) of its ownership interest is	ost %)
in the patent application/patent identified above by virtue of either:	
the United States Patent and Trademark Office at Reel copy therefore is attached.	cation/patent identified above. The assignment was recorded in 1 014941 , Frame 0853 , or for which a
OR	
	ation/patent identified above, to the current assignee as follows:
1. From:	то:
The document was recorded in the United St	tates Patent and Trademark Office at, or for which a copy thereof is attached.
2. From:	To:
The document was recorded in the United St	tates Patent and Trademark Office at
Reel, Frame	or for which a copy thereof is attached.
3. From:	To:
The document was recorded in the United St	ates Patent and Trademark Office at
Reel, Frame	or for which a copy thereof is attached.
Additional documents in the chain of title are listed on	a supplemental sheet.
As required by 37 CFR 3.73(b)(1)(f), the documentary evide or concurrently is being, submitted for recordation pursuant	ence of the chain of title from the original owner to the assignee was, to 37 CFR 3.11.
[NOTE: A separate copy (i.e., a true copy of the original ass accordance with 37 CFR Part 3, to record the assignment in	signment document(s)) must be submitted to Assignment Division in the records of the USPTO. <u>See MPEP 302.08</u>]
he undersigned (whose title) is supplied below) is authorized to ac	t on behalf of the assignee.
alu In	December 9, 2008
Signature	Date
Nan W. Hammond	760-603-2900
Printed or Typed Name	Telephone Number
Chief IP Counsel, Visigen Biotechnologies, Inc.	
Tille	
11/10	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to This consistent of information is required by 97 CP4 3.73(b). The information is required to others or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially by governed by 95 U.S. of 22 and 95 U.S. of 11 and 11.4 This collection is selementated to take 12 mittable to complete, instanced by the USPTO to proceed the selement of the USPTO to proceed the USPTO to proceed the USPTO to the USPTO the USPTO to the USPTO the USPTO to the USPTO to the USPTO to the USPTO for Patents, P.O. Box 1450. Alexandria, VA 22313-1450.